Gland Pharma Limited

rs 25

LIMITED November 29, 2022 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limi

70%

th presence across 4 FDA approved manufacturing sites in Europe (3 in France and 1 in Belgium) ➢ ~ 70%(2) of business is currently from sterile and injectable products which is expected to grow further

82%

urrently from sterile and injectable products which is expected to grow further which increases to ~82% contribution from injectables in next 4 years ➢ Significant expertise in processing specific subst

32%

72 including 1,252 employees across 4 manufacturing sites and 120 employees for services(1) Other, 32% All sites approved by FDA, EMA, ANVISA Fully integrated development and services capabilities

14%

ntegrated development and services capabilities Available site capacity to support growth PFS, 14% 4 (1) (2) (3) As of 31/12/2021. Based on 2021A CMO Revenue. Based on Sales where shipping desti

41%

E, Belgium Revenue breakdown % of 2021A CMO Revenue By Formulation By End Market(3) Ampoules, 41% South America, 5% A > North America, 1% Europe, 56% RoW, 24% Vials, 13% Asia, 14% Glan

5%

reakdown % of 2021A CMO Revenue By Formulation By End Market(3) Ampoules, 41% South America, 5% A > North America, 1% Europe, 56% RoW, 24% Vials, 13% Asia, 14% Gland Pharma Limited - A

1%

Revenue By Formulation By End Market(3) Ampoules, 41% South America, 5% A > North America, 1% Europe, 56% RoW, 24% Vials, 13% Asia, 14% Gland Pharma Limited - Acquisition of Cenexi Cen

56%

ormulation By End Market(3) Ampoules, 41% South America, 5% A > North America, 1% Europe, 56% RoW, 24% Vials, 13% Asia, 14% Gland Pharma Limited - Acquisition of Cenexi Cenexi position i

24%

By End Market(3) Ampoules, 41% South America, 5% A > North America, 1% Europe, 56% RoW, 24% Vials, 13% Asia, 14% Gland Pharma Limited - Acquisition of Cenexi Cenexi position in Pharma Va

13%

t(3) Ampoules, 41% South America, 5% A > North America, 1% Europe, 56% RoW, 24% Vials, 13% Asia, 14% Gland Pharma Limited - Acquisition of Cenexi Cenexi position in Pharma Value Chain Ce

rs 5

t of the pharma value chain No R&D risk One-stop-shop solutions High switching costs for customers 5 (1) (2) Active Pharmaceutical Ingredient. Final Dosage Form. IGLAND] Gland Pharma Limited - Acqui

“The adjusted net debt will be largely refinanced through permanent resources (GLAND] GLAND Registered Office Gland Pharma Limited Survey No.”

Corporate Office

2

Regd. Office

1

Strategic Objective

1

Cenexi Services

1

Regd. Office

Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Tel: +91-40-30510999 Fax: +91-40-30510800 India

Corporate Office

Plot N o . 11 & 84, T S I I C Phase: I V Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND PHARMA LIMITED Gland Pharma Limited Proposed Acquisition of Cenexi 29th November 2022 Cemcitibii lajectiM ■ Acquisition is subject to requisite approvals Safe Harbor Statement The Presentation is to provide the general background information about the Company’s objectives and goals as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cau

Strategic Objective

Expand our CDMO offerings in the European market, an addressable (dosage forms offered by Cenexi) FDF CDMO market of ~EUR 4 Bn in Europe and ~EUR 20 Bn globally (1) In line with our strategic roadmap of building a European manufacturing presence in sterile injectables Access to leading know-how and development capabilities in sterile forms including vials, pre-filled syringes and other innovative technologies such as ophthalmic gel and needleless injectors fill & finish Increased customer base in EU including customers in biologics area Establish our presence into the branded CDMO space (1) Source: Market Reports 3 (GLAND] Gland Pharma Limited - Acquisition of Cenexi Cenexi : Business Overview ➢ Founded in 2004, as a carve-out from Roche, Cenexi is a CDMO with sterile expertise and a track-record in ampoules, PFS and vials, and complex or niche formulations and/or dosage forms with a focus on high potent steriles and solids ➢ Revenue of EUR 184 Mn in CY21(1); EUR 100 Mn in H1’CY22 (Jan

Cenexi Services

‘Unavoidable partner’ to Cenexi customers, highly synergistic with CMO activity ▪ Dedicated, independent business with strong ties with Cenexi’s CMO activity ▪ Provides comprehensive range of services from early to late stage development to product transfer ▪ Development services strategy well aligned with CMO capabilities to ensure fast time-to-market and de- risked scale up ▪ Key part of the one-stop-shop offering, consistently bringing in recurring CMO volumes ▪ “Unavoidable” partner: 100% of customers are dealing with Cenexi Services © ✓ Development pipeline brings significant long-term and visible growth ✓ Value added partnership approach builds strong customer relationships ✓ Detailed understanding of the product from past development activity ✓ Opportunity to work on high (co-investment, value, IP innovative projects ownership) 7 GLAND Gland Pharma Limited - Acquisition of Cenexi Cenexi – Gland | A Win-Win Combination GLOBAL SCALE Become one of the leading sterile- focused CDMO

Corporate Office

Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India 3SE 543245 0NSE GLAND Bloomberg GLAND:IN 12